ZBH.SW Zimmer Biomet SIX CHF67.50 intraday 06 Feb 2026: Oversold bounce watch

ZBH.SW stock dropped to CHF67.50 intraday on SIX on 06 Feb 2026, down 4.26% from yesterday and hitting the session low. The sell-off pushed the RSI to 18.81, a clear oversold reading that often precedes a technical bounce. We track volume of 110 shares and compare the price to the 50-day average CHF78.58 and 200-day average CHF87.90 to frame a short-term rebound trade. This intraday note focuses on catalyst, technical setup, and model-driven price scenarios

ZBH.SW stock: Intraday price action and technical setup

Zimmer Biomet (ZBH.SW stock) opened and traded at CHF67.50 today on the SIX market and recorded a net change of -3.00 from the previous close of CHF70.50. The drop put the share close to its year low of CHF67.50 and well below the 50-day average CHF78.58 and 200-day average CHF87.90.

Technicals show an oversold momentum: RSI 18.81, CCI -266.00, and MACD histogram -0.32. ADX at 53.75 signals a strong directional move. For an oversold bounce strategy, traders typically look for RSI recovery above 30.00 and intraday volume pickup as confirmation.

Catalysts and near-term news drivers for ZBH.SW stock

Earnings are scheduled for 10 Feb 2026 (US release time). That calendar event is the primary catalyst that can turn an oversold bounce into a sustained move. Market commentary and sector flows in Healthcare will matter into the print.

We note limited fresh headlines today. Investors should watch surgical adoption updates, supply-chain comments, and any margin guidance in the company release. See the upcoming earnings list on MarketBeat and company detail at Zimmer Biomet.

Fundamental snapshot and valuation metrics for ZBH.SW stock

Key fundamentals: EPS CHF3.14, PE 21.50, market cap roughly CHF13,377,254,963. Price-to-book stands at 1.35 and free cash flow yield is about 7.75%. Current ratio is 2.43, and net debt to EBITDA runs near 2.87x.

Compared with the Healthcare sector average PE 34.55, Zimmer Biomet looks cheaper on PE. Still, growth is mixed: trailing net income fell year-on-year while three-year revenue per share has grown. These metrics support a recovery narrative but flag margin and leverage considerations.

Technical targets and sensible price targets for an oversold bounce

For a short-term oversold bounce, watch these levels: immediate resistance at the 50-day average CHF78.58, next resistance near CHF80.86 (Keltner upper), and stop-risk under today’s low CHF67.50. A conservative rebound target is the 50-day level CHF78.58.

A bullish intraday scenario aims for a first target CHF78.58 (implied upside 16.44%). Failure to reclaim CHF75.00 would raise odds of further weakness toward model forecasts.

Meyka AI rates ZBH.SW with a score out of 100 and model forecasts

Meyka AI rates ZBH.SW with a score out of 100: 66.74 / 100 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a yearly price of CHF56.70 and a monthly price of CHF51.98. Versus the current price CHF67.50, the yearly forecast implies -16.00% downside and the monthly model implies -22.97%. Forecasts are model-based projections and not guarantees. Use them as scenario inputs, not as firm price promises.

Risk controls, trade plan, and sector context for ZBH.SW stock

This oversold bounce trade should use tight risk controls. Suggested plan: enter on a confirmed RSI uptick above 30.00 with volume above average, set a stop at CHF66.00, and scale targets at CHF75.00 and CHF78.58. Position size should reflect volatility and account exposure to Healthcare beta.

Sector view: Healthcare on Swiss listings has outperformed year-to-date. Zimmer Biomet sits in Medical Devices and faces both cyclical surgical demand and long-term demographic tailwinds. Monitor inventory and cash conversion cycle metrics as they can pressure margins during slow demand.

Final Thoughts

ZBH.SW stock shows a textbook oversold setup after an intraday drop to CHF67.50 on SIX. The extreme momentum readings — RSI 18.81 and CCI -266.00 — increase the probability of a short-term bounce, but the trade is conditional on volume confirmation and a move back above CHF75.00. Meyka AI’s models project a yearly price CHF56.70, implying -16.00% from today, which argues caution for buy-and-hold investors. For tactical traders, a disciplined bounce play with a stop under CHF67.50, a first target at CHF75.00, and a stretch target at the 50-day average CHF78.58 balances risk and reward. Remember these are scenario-based figures, not guarantees, and our platform provides AI-powered market analysis to frame decisions rather than give investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.